The landscape of Indian laboratories is undergoing a seismic shift, driven by the rise of AI and a growing rejection of animal testing. Nearly 90% of drugs that show promise in animal trials fail in human testing, prompting a reevaluation of traditional methods. As India embraces this change, institutions like the Indian Institute of Science are pioneering AI-assisted drug discovery and organ-on-chip technologies, setting the stage for a new era in research.
However, this transition is not without its challenges. Many laboratories still rely on outdated techniques due to cost constraints and regulatory inertia. The gap between cutting-edge research and everyday laboratory practices highlights a pressing need for modernization. While elite institutions are experimenting with autonomous labs that democratize access to high-end research, the broader scientific community risks being left behind.
For India, this shift is crucial as it aligns with national initiatives like Make in India, aiming to enhance the country’s position in the global pharmaceutical landscape. By adopting more predictive and human-relevant testing models, India can improve both the efficiency of drug development and its credibility on the world stage. This is not merely an operational change; it represents a fundamental rethinking of how science is conducted in the country.
